Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Drug Fund

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

- PMLiVE

NHS England will make PrEP for HIV available in April

Will be made available to patients at risk of contracting infection

- PMLiVE

Novartis plans inclisiran trial in the UK

Swiss pharma also officially opens new London headquarters

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

- PMLiVE

Thousands of EU staffers have left NHS since 2016, says Lib Dems

Figures come from information provided by 50 NHS hospital trusts

- PMLiVE

The NHS is facing shortages of lifesaving treatments, says internal document

Identifies 17 new shortages including drugs for cancer treatment

- PMLiVE

Election 2019: Labour tops Tory pledge on NHS spending

Pledge comes as campaigning for upcoming election gathers steam

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

- PMLiVE

NHS leader warns politicians not to ‘weaponise’ the health service

Top exec challenges main parties to provide credible solutions to big issues

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Labour party plans to abolish NHS prescription charges

Comes amid increased focus on drug pricing in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links